Altis Labs, Inc. (Altis), an innovative computational imaging firm, spearheads a worldwide coalition to push for the use of digital twins in clinical trials. This group aims to change the clinical trial design, speed up timelines, and lower failure rates for new cancer treatments.
Digital twins, or virtual replicas of physical systems, enable real-time monitoring and manipulation. In healthcare, professionals use them to simulate patient responses to treatments.
AstraZeneca and Bayer Pharmaceuticals apply these predictions to refine statistical analyses. This enhances treatment assessment accuracy and speeds up candidate prioritisation. Altis’ flagship platform, Nota, helps biopharma sponsors analyse imaging data from ongoing and past trials using AI models. These models forecast disease progression for patients, forming a virtual control group of digital twins. The project has been met with great excitement as it leverages AI tools to improve patient outcomes while building on Altis’ success in developing a substantial cancer imaging database.
AstraZeneca and Bayer Pharmaceuticals, as early adopters, have exclusive access to AI models through Nota for four clinical trials. DIGITAL, Canada’s top Innovation Cluster for digital technologies, backs this $5.7 million project.
The transformative potential of AI-based digital twins to provide insights beyond traditional tumour measurements is clear, reinforcing the crucial role of clinical trials. This initiative, merging Canada’s AI capabilities and healthcare systems, plays a significant role in adopting clinical research tools. The ultimate aim is to revolutionise therapeutic development and enhance the quality and accessibility of cancer care in Canada.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
#SyenzaNews #globalhealth #healthcareInnovation
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
#SyenzaNews #globalhealth #HealthcareInnovation
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
